Effects of an Inhibitor of 3beta-Hydroxysteroid Dehydrogenase on Glucose, Lipid Metabolism and Adipose Tissue in a Patient With Type 2 Diabetes

Abstract

Elevated serum levels of glucocorticoids promote visceral obesity, hyperlipidemia, insulin resistance, as observed in patients with Cushings syndrome. Trilostane inhibits the synthesis of cortisol by competitive and reversible blocking of 3beta-hydroxysteroid dehydrogenase, and is used in the treatment of Cushings syndrome. We studied effects of trilostane on glucose, lipid metabolism and adipose tissue in a patient with type 2 diabetes who was complicated with Cushings syndrome. Trilostane significantly reduced visceral fat, serum lipoproteins including atherogenic lipoproteins, and also increased serum adiponectin in this patient, proposing a new approach for the treatment of obesity and metabolic syndrome.




J Endocrinol Metab. 2013;3(4-5):119-123
doi: https://doi.org/10.4021/jem180w